Chargement en cours...
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
BACKGROUND: Patients with autoimmune diseases were not evaluated in clinical trials with immune checkpoint inhibitors (ICIs), since a history of immune disorders, such as Guillain–Barré syndrome (GBS) and psoriasis, is one of the major risk factors for the development of immune-related adverse event...
Enregistré dans:
| Publié dans: | Case Rep Oncol Med |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Hindawi
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5863341/ https://ncbi.nlm.nih.gov/pubmed/29707397 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/2783917 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|